Zhejiang Chimin Pharm Co Ltd (603222) - Net Assets
Based on the latest financial reports, Zhejiang Chimin Pharm Co Ltd (603222) has net assets worth CN¥1.20 Billion CNY (≈ $175.70 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.27 Billion ≈ $331.94 Million USD) and total liabilities (CN¥1.07 Billion ≈ $156.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603222 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.20 Billion |
| % of Total Assets | 52.93% |
| Annual Growth Rate | 9.15% |
| 5-Year Change | -5.02% |
| 10-Year Change | 61.39% |
| Growth Volatility | 21.2 |
Zhejiang Chimin Pharm Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Zhejiang Chimin Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. See 603222 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Chimin Pharm Co Ltd (2011–2025)
The table below shows the annual net assets of Zhejiang Chimin Pharm Co Ltd from 2011 to 2025. For live valuation and market cap data, see market value of Zhejiang Chimin Pharm Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.31 Billion ≈ $191.04 Million |
-16.75% |
| 2024-12-31 | CN¥1.57 Billion ≈ $229.47 Million |
-5.52% |
| 2023-12-31 | CN¥1.66 Billion ≈ $242.89 Million |
-6.46% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.65 Million |
+29.09% |
| 2021-12-31 | CN¥1.37 Billion ≈ $201.14 Million |
+31.38% |
| 2020-12-31 | CN¥1.05 Billion ≈ $153.10 Million |
-2.47% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.99 Million |
+2.50% |
| 2018-12-31 | CN¥1.05 Billion ≈ $153.15 Million |
+12.74% |
| 2017-12-31 | CN¥928.28 Million ≈ $135.84 Million |
+14.75% |
| 2016-12-31 | CN¥808.94 Million ≈ $118.37 Million |
+7.72% |
| 2015-12-31 | CN¥750.99 Million ≈ $109.89 Million |
+70.08% |
| 2014-12-31 | CN¥441.55 Million ≈ $64.61 Million |
-9.54% |
| 2013-12-31 | CN¥488.13 Million ≈ $71.43 Million |
+12.86% |
| 2012-12-31 | CN¥432.53 Million ≈ $63.29 Million |
+12.92% |
| 2011-12-31 | CN¥383.04 Million ≈ $56.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Chimin Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 43.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥73.89 Million | 6.06% |
| Other Components | CN¥1.15 Billion | 93.94% |
| Total Equity | CN¥1.22 Billion | 100.00% |
Zhejiang Chimin Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Chimin Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SANTANDER UK 8 5/8% NON-CUM STLG PRF
LSE:SANB
|
$536.49 Million |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
$536.51 Million |
|
ZF Commercial Vehicle Control Systems India Limited
NSE:ZFCVINDIA
|
$536.61 Million |
|
Neuropace Inc
NASDAQ:NPCE
|
$536.64 Million |
|
Napatech A/S
OL:NAPA
|
$536.29 Million |
|
Nanjing Baose Co Ltd
SHE:300402
|
$536.28 Million |
|
Esso S.A.F.
PA:ES
|
$535.78 Million |
|
ZimVie Inc
NASDAQ:ZIMV
|
$535.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Chimin Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,480,824,869 to 1,219,425,659, a change of -261,399,210 (-17.7%).
- Net loss of 245,582,547 reduced equity.
- Dividend payments of 19,757,012 reduced retained earnings.
- Other comprehensive income decreased equity by 36,740,021.
- Other factors increased equity by 40,680,371.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-245.58 Million | -20.14% |
| Dividends Paid | CN¥19.76 Million | -1.62% |
| Other Comprehensive Income | CN¥-36.74 Million | -3.01% |
| Other Changes | CN¥40.68 Million | +3.34% |
| Total Change | CN¥- | -17.65% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Chimin Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.07x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.15 | CN¥6.98 | x |
| 2012-12-31 | CN¥1.28 | CN¥6.98 | x |
| 2013-12-31 | CN¥1.46 | CN¥6.98 | x |
| 2014-12-31 | CN¥1.31 | CN¥6.98 | x |
| 2015-12-31 | CN¥1.69 | CN¥6.98 | x |
| 2016-12-31 | CN¥1.71 | CN¥6.98 | x |
| 2017-12-31 | CN¥1.82 | CN¥6.98 | x |
| 2018-12-31 | CN¥1.80 | CN¥6.98 | x |
| 2019-12-31 | CN¥1.98 | CN¥6.98 | x |
| 2020-12-31 | CN¥1.93 | CN¥6.98 | x |
| 2021-12-31 | CN¥2.60 | CN¥6.98 | x |
| 2022-12-31 | CN¥3.47 | CN¥6.98 | x |
| 2023-12-31 | CN¥2.89 | CN¥6.98 | x |
| 2024-12-31 | CN¥2.73 | CN¥6.98 | x |
| 2025-12-31 | CN¥2.32 | CN¥6.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Chimin Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.80%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.89x
- Recent ROE (-20.14%) is below the historical average (5.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 17.69% | 12.36% | 0.84x | 1.71x | CN¥29.47 Million |
| 2012 | 17.24% | 12.79% | 0.84x | 1.60x | CN¥31.31 Million |
| 2013 | 16.64% | 14.52% | 0.78x | 1.46x | CN¥32.43 Million |
| 2014 | 13.04% | 11.79% | 0.78x | 1.43x | CN¥13.43 Million |
| 2015 | 7.18% | 11.54% | 0.53x | 1.17x | CN¥-20.36 Million |
| 2016 | 5.44% | 9.08% | 0.49x | 1.23x | CN¥-34.23 Million |
| 2017 | 6.67% | 8.77% | 0.38x | 1.98x | CN¥-26.46 Million |
| 2018 | 3.96% | 4.59% | 0.33x | 2.62x | CN¥-48.91 Million |
| 2019 | 7.93% | 8.97% | 0.37x | 2.39x | CN¥-18.01 Million |
| 2020 | 0.74% | 0.73% | 0.38x | 2.65x | CN¥-80.08 Million |
| 2021 | 11.91% | 13.43% | 0.45x | 1.96x | CN¥23.68 Million |
| 2022 | 2.02% | 4.12% | 0.31x | 1.59x | CN¥-136.24 Million |
| 2023 | -4.15% | -7.32% | 0.36x | 1.57x | CN¥-223.09 Million |
| 2024 | -4.03% | -7.70% | 0.32x | 1.63x | CN¥-207.79 Million |
| 2025 | -20.14% | -35.80% | 0.30x | 1.89x | CN¥-367.53 Million |
Industry Comparison
This section compares Zhejiang Chimin Pharm Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,912,485,544
- Average return on equity (ROE) among peers: 0.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Chimin Pharm Co Ltd (603222) | CN¥1.20 Billion | 17.69% | 0.89x | $536.32 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $911.32 Million | 9.77% | 4.17x | $467.27 Million |
| Blue Sail Medical Co Ltd (002382) | $9.55 Billion | -5.95% | 0.64x | $762.28 Million |
| Andon Health Co Ltd (002432) | $1.54 Billion | 0.94% | 0.53x | $4.53 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $994.18 Million | 15.79% | 0.86x | $842.34 Million |
| Guangzhou Improve Med Instrument (300030) | $643.86 Million | -18.31% | 0.93x | $264.68 Million |
| QITIAN Technology Group Co Ltd (300061) | $1.16 Billion | -31.55% | 0.49x | $662.48 Million |
| Shanghai Tofflon Science Tech (300171) | $8.11 Billion | 7.40% | 0.59x | $1.21 Billion |
| Truking Technology Ltd (300358) | $4.32 Billion | -10.48% | 2.08x | $790.04 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $207.61 Million | 23.43% | 0.59x | $680.70 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.69 Billion | 14.20% | 0.20x | $1.39 Billion |
About Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, in… Read more